Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients
Author:
Funder
Pfizer Inc
Publisher
Elsevier BV
Subject
Orthopedics and Sports Medicine,Biomedical Engineering,Rheumatology
Reference43 articles.
1. S. B. Abramson, M. Attur, and Y. Yazici, “Prospects for disease modification in osteoarthritis,” Nat Clin Pract Rheumatol, vol. 2, no. 6. pp. 304–312.
2. T. J. Schnitzer et al., “Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain,” AnnRheumDis, vol. 74, no. 6. pp. 1202–1211.
3. E. F. Ekman et al., “Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen,” JRheumatol, vol. 41, no. 11. pp. 2249–2259.
4. M. T. Brown, F. T. Murphy, D. M. Radin, I. Davignon, M. D. Smith, and C. R. West, “Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial,” J Pain, vol. 13, no. 8. pp. 790–798.
5. M. C. Hochberg et al., “When is osteonecrosis not osteonecrosis?: Adjudication of reported serious adverse joint events in the tanezumab clinical development program,” Arthritis Rheum, vol. 68, no. 2. pp. 382–391.
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Endophenotypes of Primary Osteoarthritis of the Hip Joint in the Bulgarian Population over 60 Years Old;Life;2024-05-11
2. Osteoarthritis year in review 2022: Epidemiology & therapy;Osteoarthritis and Cartilage;2023-07
3. Osteoarthritis: pathogenic signaling pathways and therapeutic targets;Signal Transduction and Targeted Therapy;2023-02-03
4. Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?;Osteoarthritis and Cartilage Open;2022-09
5. Does anti-nerve growth factor monoclonal antibody treatment have the potential to replace nonsteroidal anti-inflammatory drugs and opioids in treating hip or knee osteoarthritis? A systematic review of randomized controlled trials;EFORT Open Reviews;2022-07-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3